Browsing by Author "J. Shukla"

Now showing 1 - 9 of 9

Acute megaloblastic reaction in hereditary spherocytosis.
(1993) J. Shukla; O.P. Mishra; G.P. Katiyar; B. Dube
[No abstract available]
Autoimmune hemolytic anemia
(2008) V. Gupta; J. Shukla; B.D. Bhatia
Objective. To study the clinico-hematological profile and treatment outcome in children suffering from auto immune hemolytic anemia (AIHA). Methods. Twelve children were diagnosed with auto immune hemolytic anemia over a period of four years. Direct antiglobulin test was positive in all the cases. Other causes of hemolytic anemia like thalassemia syndromes, hereditary spherocytosis, G6PD deficiency were excluded by appropriate tests. The children were followed up for 6 months to 4 years. Results. The age ranged from 7 mth to 9 yr with a mean age of 4.51 yr. All patients had pallor as the presenting complaint followed by splenomegaly (83.3%), jaundice (66.7%), fever (50%) and bleeding manifestations (16.7%). 9 patients had primary disease and 3 had secondary disease. Tubercular infection was seen in 2 patients with secondary disease. Jaundice was seen equally in both the groups. Oral prednisolone produced remission in 83.3% cases. 4 patients (3 in primary and one in secondary group) had relapse after initial response. All responded to a second course of steroids but had subsequent relapses and developed a chronic course. Conclusion. Autoimmune hemolytic anemia is an uncommon cause of hemolytic anemia in children. Tubercular infection is an underlying pathology in cases of secondary autoimmune hemolytic anemia. Although oral steroids induce remission in most of the cases, relapses are common. © 2008 Dr. K C Chaudhuri Foundation.
Congenital factor XIII deficiency.
(1993) J. Shukla; B. Dube; R.K. Dube; B.K. Das; O.P. Mishra
[No abstract available]
Down's syndrome with acute myeloid leukemia.
(1994) V.P. Singh; S. Sundar; K. Kumar; J. Shukla; B. Dube
[No abstract available]
Functional and radiological assessment of arthropathy in Indian children with haemophilia
(2013) V. Gupta; H.S. Sandeep; A. Rai; J. Shukla
[No abstract available]
Low Dose Cyclosporine-A Therapy in Severe Aplastic Anaemia
(2001) M. Rai; V.P. Singh; J. Shukla; S. Sundar; V.C. Jha
Objective : The present study was conducted to evaluate the efficacy of low dose cyclosporine-A in the patients of severe aplastic anaemia, who cannot afford allogenic bone marrow transplantation and immunosuppressive therapy with antithymocyte globulin. Methods : The diagnosis of severe aplastic anaemia was established by standard criteria. Twelve patients were given cyclosporine-A orally at a dose of 6 mg/kg body weight in divided doses in two daily equal proportions for six months. Eleven patients were put on oral stanozolol in the dosage of 1 mg/kg body weight/day in divided doses. All surviving patients were evaluated at three and six months. Results : At the end of six months, 41.66% of twelve patients responded to cyclosporine-A. One patient had complete response and four patients had partial response. Only one out of 11 patients receiving stanozolol responded. Conclusions : i) Cyclosporine-A is a viable therapeutic option in the treatment of severe aplastic anaemia, ii) Low dose cyclosporine-A is able to slow down the stormy course of the severe aplastic anaemia, iii) Androgens have very little effect on the survival of patients of severe aplastic anaemia.
Myelodysplastic syndrome
(2008) V. Tilak; D.D. Sookmane; V. Gupta; J. Shukla
Pediatric myelodysplastic syndrome (MDS), though rare, constitutes a distinct entity quite different from adult MDS. They have unique clinical features, aggressive clinical course with an overall mean survival of only 9.9 months. A pediatric approach to the WHO classification has become necessary since the WHO classification of MDS has failed to address the uniqueness of pediatric MDS. A new prognostic system also needs to be evolved since the international prognostic system has limited prognostic impact in children. Intensive chemotherapy such as the one used in de novo-acute myeloid leukemia (AML) leads to complete remission in some children and this may be the treatment of choice in pediatric MDS. © 2008 Dr. K C Chaudhuri Foundation.
Non-Hodgkin's Lymphoma with Pure Red Cell Aplasia
(2001) V.P. Singh; A. Khanna; M. Rai; S. Sundar; P.K. Shukla; T. Naresh; J. Shukla
Pure red cell aplasia (PRCA) associated with non-Hodgkin's lymphoma, is an extremely rare condition, with few cases reported worldwide. More commonly PRCA is associated with thymoma or viral infections. Steroids and other immunosuppressive drugs are the preferred treatment of PRCA.
Plasma cell leukemia--report on two cases.
(1994) V.P. Singh; S. Sundar; K. Kumar; J. Shukla; B. Dube
[No abstract available]